Manolo Mugnaini, a principal research scientist at AbbVie's Discovery Neuroscience Centre in Ludwigshafen, Germany, brings more than 30 years of industry experience in pharmaceutical companies (GlaxoSmithKline, AbbVie) and contract research organizations (Aptuit). He has significantly contributed to research programs across all stages of the drug discovery process. Dr. Mugnaini specializes in radioligand binding and autoradiography for target occupancy determination and translational research. His expertise also includes drug-receptor interaction theory, in situ hybridization, immunohistochemistry and neuroanatomy of rodents and primates, including humans. Dr. Mugnaini's recent research has focused on developing PET tracers to monitor disease progression and drug efficacy in neurodegenerative diseases such as Alzheimer’s disease, progressive supranuclear palsy, Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy. Additionally, his work encompasses the discovery of drugs targeting dopamine D3 receptors and a subtype of acetylcholine receptors for the treatment of substance-use disorders.